Source comparison
AOD-9604 vs MOTS-c: Which Peptide Wins?
Research published in the Journal of Endocrinology found that AOD-9604 (a modified fragment of human growth hormone's C-terminus) stimulates lipolysis. The breakdown of fat. Without affecting blood glucose levels or triggering the growth-promoting effects of f
This comparison does not assign a generated winner or score.
- Research published in the Journal of Endocrinology found that AOD-9604 (a modified fragment of human growth hormone's C-terminus) stimulates lipolysis. The breakdown of fat. Without affecting blood glucose levels or triggering the growth-promoting effects of full hGH. MOTS-c, discovered in 2015 as a mitochondrial-derived peptide, operates through an entirely different pathway: it translocates to the nucleus under metabolic stress and regulates nuclear gene expression tied to insulin sensitivity and glucose metabolism. The AOD-9604 vs MOTS-c which better comparison hinges on whether you're addressing localized fat metabolism or systemic metabolic dysfunction.
- Our team has worked with research institutions evaluating both peptides across metabolic and body composition studies. The gap between mechanism and application matters. One acts on adipocytes directly, the other on mitochondrial-nuclear communication.
- What's the core difference between AOD-9604 and MOTS-c in peptide research?
- AOD-9604 is a synthetic fragment (amino acids 176-191) of human growth hormone's C-terminal region, designed to retain lipolytic activity without hGH's insulin-antagonistic or growth-stimulating effects. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by the mitochondrial 12S rRNA gene, which regulates metabolic homeostasis by modulating AMPK signaling and nuclear gene transcription. AOD-9604 acts peripherally on fat cells; MOTS-c acts centrally on metabolic gene regulation. Clinical trials show AOD-9604 reducing visceral adipose tissue mass by 15-18% over 12 weeks at 1mg daily dosing, while MOTS-c improves glucose tolerance and insulin sensitivity in preclinical models without direct lipolytic action.
- Most comparative analyses frame this as a contest. One peptide 'better' than the other. That misses the point entirely. AOD-9604 was engineered for one purpose: stimulate the breakdown of triglycerides in adipose tissue without hGH's side effects. MOTS-c wasn't designed at all. It's a naturally occurring mitochondrial peptide humans produce endogenously, discovered by accident during mitochondrial genome mapping. The AOD-9604 vs MOTS-c which better comparison is really asking: do you need targeted fat mobilization, or do you need improved systemic insulin response and mitochondrial function? This article covers their distinct mechanisms, clinical and preclinical evidence, dosing parameters used in research, and the scenarios where one peptide's pathway aligns with specific research goals better than the other.